Skip to main content
Erschienen in: Supportive Care in Cancer 8/2011

01.08.2011 | Short Communication

Comparison of SF-36 vitality scale and Fatigue Symptom Inventory in assessing cancer-related fatigue

verfasst von: Linda F. Brown, Kurt Kroenke, Dale E. Theobald, Jingwei Wu

Erschienen in: Supportive Care in Cancer | Ausgabe 8/2011

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Cancer-related fatigue (CRF) is an important symptom in clinical practice and research. The best way to measure it, however, remains unsettled. The SF-36 vitality scale, a general measure of energy/fatigue, is a frequently cited measure. With only four items, however, its ability to adequately represent multiple CRF facets has been questioned. The 13-item Fatigue Symptom Inventory (FSI) was developed to assess multidimensional aspects of CRF. Our objectives were to assess the convergent validity and to compare the sensitivity to change of the two scales.

Methods

We administered both scales at 1 month (n = 68) and 6 months (n = 96) to a subset of heterogeneous patients receiving treatment in 16 cancer centers who were enrolled in a clinical trial of pain and depression. Distributions of standardized response means (SRMs) were compared to assess sensitivity to change. Results of both scales were compared to scores on a single fatigue item from the Patient Health Questionnaire (PHQ).

Results

Mean scores for both the FSI and the vitality scale demonstrated clinically significant fatigue in the sample. The vitality scale was strongly correlated with all three FSI scales (r = −0.68 to −0.77). The vitality and FSI scales also correlated strongly with the PHQ fatigue item. Moreover, distributions of SRMs for both scales were approximately normal.

Conclusions

Both the FSI and the vitality scale are supported as valid measures of CRF. Both demonstrated sensitivity to change across a range of effect sizes. The vitality scale may be an excellent choice when brevity is paramount; the FSI may be more appropriate when tapping specific dimensions is warranted.
Literatur
1.
Zurück zum Zitat Hofman M, Ryan JL, Figueroa-Moseley CD, Jean-Pierre P, Morrow GR (2007) Cancer-related fatigue: the scale of the problem. Oncologist 12(Supplement 1):4–10PubMedCrossRef Hofman M, Ryan JL, Figueroa-Moseley CD, Jean-Pierre P, Morrow GR (2007) Cancer-related fatigue: the scale of the problem. Oncologist 12(Supplement 1):4–10PubMedCrossRef
2.
Zurück zum Zitat Berger AM, Abernethy AP, Atkinson A, Barsevick AM, Cella D, Cimprich B, Cleeland CS, Eisenberger MA, Escalante CP, Hinds P, Jacobsen PB, Kaldor P, Ligibel JA, Loscalzo MJ, Murphy BA, O’Connor T, Pirl WF, Rodler E, Rugo HS, Wagner LI (2009) Nccn clinical practice guidelines in oncology: Cancer-related fatigue. National Comprehensive Cancer Network. 2009 Berger AM, Abernethy AP, Atkinson A, Barsevick AM, Cella D, Cimprich B, Cleeland CS, Eisenberger MA, Escalante CP, Hinds P, Jacobsen PB, Kaldor P, Ligibel JA, Loscalzo MJ, Murphy BA, O’Connor T, Pirl WF, Rodler E, Rugo HS, Wagner LI (2009) Nccn clinical practice guidelines in oncology: Cancer-related fatigue. National Comprehensive Cancer Network. 2009
3.
Zurück zum Zitat Patrick DL, Ferketich SL, Frame PS, Harris JJ, Hendricks CB, Levin B, Link MP, Lustig C, McLaughlin J, Reid LD, Turrisi ATr, Unutzer J, Vernon SW (2002) Symptom management in cancer: pain, depression, and fatigue. NIH Consens Statements State Sci Statements 19(4):1–29 Patrick DL, Ferketich SL, Frame PS, Harris JJ, Hendricks CB, Levin B, Link MP, Lustig C, McLaughlin J, Reid LD, Turrisi ATr, Unutzer J, Vernon SW (2002) Symptom management in cancer: pain, depression, and fatigue. NIH Consens Statements State Sci Statements 19(4):1–29
5.
Zurück zum Zitat Jacobsen PB (2004) Assessment of fatigue in cancer patients. J Natl Cancer Inst Monogr 32:93–97PubMedCrossRef Jacobsen PB (2004) Assessment of fatigue in cancer patients. J Natl Cancer Inst Monogr 32:93–97PubMedCrossRef
6.
Zurück zum Zitat Jean-Pierre P, Figueroa-Moseley CD, Kohli S, Fiscella K, Palesh OG, Morrow GR (2007) Assessment of cancer-related fatigue: implications for clinical diagnosis and treatment. Oncologist 12(Supplement 1):11–21PubMedCrossRef Jean-Pierre P, Figueroa-Moseley CD, Kohli S, Fiscella K, Palesh OG, Morrow GR (2007) Assessment of cancer-related fatigue: implications for clinical diagnosis and treatment. Oncologist 12(Supplement 1):11–21PubMedCrossRef
7.
Zurück zum Zitat Cella D, Lai J-S, Stone A (2010) Self-reported fatigue: One dimension or more? Lessons from the functional assessmet of chronic illness therapy–fatigue (facit-f) questionnaire. Support Care Cancer Published online August 13:2010 Cella D, Lai J-S, Stone A (2010) Self-reported fatigue: One dimension or more? Lessons from the functional assessmet of chronic illness therapy–fatigue (facit-f) questionnaire. Support Care Cancer Published online August 13:2010
8.
Zurück zum Zitat Ware JE, Kosinski M, Keller SD (1994) Sf-36 physical and mental health summary scales: a user’s manual. The Health Institute, New England Medical Center, Boston Ware JE, Kosinski M, Keller SD (1994) Sf-36 physical and mental health summary scales: a user’s manual. The Health Institute, New England Medical Center, Boston
9.
Zurück zum Zitat O’Connor PJ (2004) Evaluation of four highly cited energy and fatigue mood measures. J Psychosom Res 57:435–441PubMedCrossRef O’Connor PJ (2004) Evaluation of four highly cited energy and fatigue mood measures. J Psychosom Res 57:435–441PubMedCrossRef
10.
Zurück zum Zitat Kroenke K, Theobald D, Norton K, Sanders R, Schlundt S, McCalley S, Harvey P, Iseminger K, Morrison G, Carpenter JS, Stubbs D, Jacks R, Carney-Doebbeling C, Wu J, Tu W (2009) The indiana cancer pain and depression (incpad) trial: design of a telecare management intervention for cancer-related symptoms and baseline characteristics of study participants. Gen Hosp Psychiatry 31:240–253PubMedCrossRef Kroenke K, Theobald D, Norton K, Sanders R, Schlundt S, McCalley S, Harvey P, Iseminger K, Morrison G, Carpenter JS, Stubbs D, Jacks R, Carney-Doebbeling C, Wu J, Tu W (2009) The indiana cancer pain and depression (incpad) trial: design of a telecare management intervention for cancer-related symptoms and baseline characteristics of study participants. Gen Hosp Psychiatry 31:240–253PubMedCrossRef
11.
Zurück zum Zitat Kroenke K, Theobald D, Wu J, Norton K, Morrison G, Carpenter JS, Tu W (2010) Effect of telecare management on pain and depression in patients with cancer: a randomized trial. JAMA 304(2):163–171PubMedCrossRef Kroenke K, Theobald D, Wu J, Norton K, Morrison G, Carpenter JS, Tu W (2010) Effect of telecare management on pain and depression in patients with cancer: a randomized trial. JAMA 304(2):163–171PubMedCrossRef
12.
Zurück zum Zitat Ware JE, Snow KK, Kosinski M, Gandek B (1993) Sf-36 health survey: manual and interpretation guide. The Health Institute, New England Medical Center, Boston Ware JE, Snow KK, Kosinski M, Gandek B (1993) Sf-36 health survey: manual and interpretation guide. The Health Institute, New England Medical Center, Boston
13.
Zurück zum Zitat Wu H-S, McSweeney M (2004) The assessment and measurement of fatigue in people with cancer. In: Armes J, Krishnasamy M, Higgenson I (eds) Fatigue in cancer. Oxford University Press, Oxford, pp 193–221 Wu H-S, McSweeney M (2004) The assessment and measurement of fatigue in people with cancer. In: Armes J, Krishnasamy M, Higgenson I (eds) Fatigue in cancer. Oxford University Press, Oxford, pp 193–221
14.
Zurück zum Zitat Donovan KA, Jacobsen PB, Small BJ, Munster PN, Andrykowski MA (2008) Identifying clinically meaningful fatigue with the fatigue symptom inventory. J Pain Symptom Manage 36(5):480–487PubMedCrossRef Donovan KA, Jacobsen PB, Small BJ, Munster PN, Andrykowski MA (2008) Identifying clinically meaningful fatigue with the fatigue symptom inventory. J Pain Symptom Manage 36(5):480–487PubMedCrossRef
15.
Zurück zum Zitat Shun S-C, Beck SL, Pett MA, Richardson SJ (2007) Assessing responsiveness of cancer-related fatigue instruments: distribution-based and individual-based anchors. Oncologist 12:495–504PubMedCrossRef Shun S-C, Beck SL, Pett MA, Richardson SJ (2007) Assessing responsiveness of cancer-related fatigue instruments: distribution-based and individual-based anchors. Oncologist 12:495–504PubMedCrossRef
16.
Zurück zum Zitat Kroenke K, Spitzer RL, Williams JBW (2001) The phq-15: validity of a new measure for evaluating somatic symptom severity. Psychosomatic Medicine 64 Kroenke K, Spitzer RL, Williams JBW (2001) The phq-15: validity of a new measure for evaluating somatic symptom severity. Psychosomatic Medicine 64
17.
Zurück zum Zitat Kroenke K, West SL, Swindle R, Gilsenan A, Eckert GJ, Dolor R et al (2001) Similar effectiveness of paroxetine, fluoxetine, and sertraline in primary care: a randomized trial. JAMA 286:2947–2955PubMedCrossRef Kroenke K, West SL, Swindle R, Gilsenan A, Eckert GJ, Dolor R et al (2001) Similar effectiveness of paroxetine, fluoxetine, and sertraline in primary care: a randomized trial. JAMA 286:2947–2955PubMedCrossRef
18.
Zurück zum Zitat Unutzer J, Katon W, Callahan CM, Williams JW Jr, Hunkeler EM, Harpole L, Hoffing M, Della Penna RD, Noel PH, Lin EHB, Arean PA, Hegel MT, Tang L, Belin TR, Oishi S, Langston C (2002) Collaborative care management of late-life depression in the primary care setting. JAMA 288(22):2836–2845PubMedCrossRef Unutzer J, Katon W, Callahan CM, Williams JW Jr, Hunkeler EM, Harpole L, Hoffing M, Della Penna RD, Noel PH, Lin EHB, Arean PA, Hegel MT, Tang L, Belin TR, Oishi S, Langston C (2002) Collaborative care management of late-life depression in the primary care setting. JAMA 288(22):2836–2845PubMedCrossRef
19.
Zurück zum Zitat Devo RA, Diehr P, Patrick DL (1991) Reproducibility and responsiveness of health status measures; statistics and strategies for evaluation. Control Clin Trials 12:142S–158SCrossRef Devo RA, Diehr P, Patrick DL (1991) Reproducibility and responsiveness of health status measures; statistics and strategies for evaluation. Control Clin Trials 12:142S–158SCrossRef
20.
Zurück zum Zitat Katz JN, Larson MG, Phillips CB, Fossel AH, Liang MH (1992) Comparative measurement sensitivity of short and longer health status instruments. Med Care 30(10):917–925PubMedCrossRef Katz JN, Larson MG, Phillips CB, Fossel AH, Liang MH (1992) Comparative measurement sensitivity of short and longer health status instruments. Med Care 30(10):917–925PubMedCrossRef
21.
Zurück zum Zitat Wright JG, Young NL (1997) A comparison of different indices of responsiveness. J Clin Epidemiol 50(3):239–246PubMedCrossRef Wright JG, Young NL (1997) A comparison of different indices of responsiveness. J Clin Epidemiol 50(3):239–246PubMedCrossRef
22.
Zurück zum Zitat Jacobsen PB, Donovan KA, Weitzner M (2003) Distinguishing fatigue and depression in patients with cancer. Semin Clin Neuropsychiatry 8(4):229–240PubMed Jacobsen PB, Donovan KA, Weitzner M (2003) Distinguishing fatigue and depression in patients with cancer. Semin Clin Neuropsychiatry 8(4):229–240PubMed
Metadaten
Titel
Comparison of SF-36 vitality scale and Fatigue Symptom Inventory in assessing cancer-related fatigue
verfasst von
Linda F. Brown
Kurt Kroenke
Dale E. Theobald
Jingwei Wu
Publikationsdatum
01.08.2011
Verlag
Springer-Verlag
Erschienen in
Supportive Care in Cancer / Ausgabe 8/2011
Print ISSN: 0941-4355
Elektronische ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-011-1148-2

Weitere Artikel der Ausgabe 8/2011

Supportive Care in Cancer 8/2011 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.